共检索14条数据Total:14
2021-02-28
Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Hubei, China.; Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Hubei, China.; Township government of Shanpo, Jiangxia District, Wuhan, Hubei, China.; Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Hubei, China.; Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Hubei, China.; Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Hubei, China.
2021-02-10
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China. Electronic address: qingleigao@hotmail.com.
Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for
2021-05-17
Department of Nephrology, Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, Central Hospital of Wuhan City, Wuhan, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Department of Nephrology, Xiangya Hospital of Central South University, Changsha, China.; Department of Nephrology, Xiangya Hospital of Central South University, Changsha, China.; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.; Organ Fibrosis Key Laboratory of Hunan Province, Changsha, China.
Background: A large number of people contracted moderate-type COVID-19 around the world. However, to our knowledge no studies have covered the clinical course of patients with moderate-type COVID-19. This study describes the clinical course of moderate-type patients with COVID-19 from Wuhan City and Yiyang City, and explores factors relevant to the length of hospitalization and symptoms relief. Methods: The study analyzed the clinical course of 107 moderate-type patients with COVID-19 from the outbreak area (Wuhan) and the imported area (Yiyang), and used automatic linear modeling and multivariate linear regression analysis to explore the factors relevant to the length of hospitalization and symptoms relief. Furthermore, we created a scoring system to value the length of hospitalization and symptoms relief. Results: Lymphopenia, elevated C-reactive protein, increased LDH, bilateral lung GGO (ground glass opacity), and lung consolidation were more likely to appear in ordinary
2021-05-13
Development and Planning Department, Chongqing Medical University, Chongqing, China.; School of Economics and Management, Wuhan University, Wuhan, China.; Neurology Department, The 987 Hospital of PLA, Baoji, China.; Xinqiao Hospital, Army Medical University, No. 83 Xinqiao Zhengjie, Shapingba District, Chongqing, China.; Department of Medical Administration, Southwest Hospital, Army Medical University, Chongqing, China.; Chongqing Health Center for Women and Children, No.120 Longshan Road, Yubei District, Chongqing, China.; Xinqiao Hospital, Army Medical University, No. 83 Xinqiao Zhengjie, Shapingba District, Chongqing, China. ewuhao@163.com.; Chongqing Health Center for Women and Children, No.120 Longshan Road, Yubei District, Chongqing, China. 1215860285@qq.com.
BACKGROUND: With the increasing spread of COVID-19, healthcare workers, especially front-line medical staff, have become more vulnerable to emotional exhaustion. OBJECTIVES: This study aimed to determine the influence of time pressure on the emotional exhaustion of front-line healthcare workers, and explore the effects of social sharing and cognitive reappraisal on this. METHODS: This cross-sectional study was conducted in March 2020. A total of 232 questionnaires were completed by front-line healthcare workers in Wuhan city, Hubei province, China. Hierarchical linear regression and conditional process analysis were performed to explore the relationships among time pressure, social sharing, cognitive reappraisal, and emotional exhaustion. RESULTS: Time pressure was positively associated with social sharing and emotional exhaustion. Social sharing presented the dark side, a negative effect that was always kept concealed, in terms of the impact on emotional exhaustion. Cognitive
2021-10-03
Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
BACKGROUND: The global outbreak of coronavirus disease 2019 (COVID-19) has turned into a worldwide public health crisis and caused more than 100,000,000 severe cases. Progressive lymphopenia, especially in T cells, was a prominent clinical feature of severe COVID-19. Activated HLA-DR(+)CD38(+) CD8(+) T cells were enriched over a prolonged period from the lymphopenia patients who died from Ebola and influenza infection and in severe patients infected with SARS-CoV-2. However, the CD38(+)HLA-DR(+) CD8(+) T population was reported to play contradictory roles in SARS-CoV-2 infection. METHODS: A total of 42 COVID-19 patients, including 32 mild or moderate and 10 severe or critical cases, who received care at Beijing Ditan Hospital were recruited into this retrospective study. Blood samples were first collected within 3 days of the hospital admission and once every 3-7 days during hospitalization. The longitudinal flow cytometric data were examined during hospitalization. Moreover, we
2021-04-19
Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Medical College of Nanchang University.; Department of Gastroenterology Medicine, The Third Affiliated Hospital of Nanchang University, Nanchang, China.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University.
Pediatric cases of coronavirus disease 2019 (COVID-19) have been reported. This meta-analysis was aimed at describing the clinical, laboratory, and imaging characteristics of children with COVID-19 based on published data of pediatric COVID-19 cases.Search of PubMed, Embase, Web of Sciences, Science Direct, and Google Scholar for articles published until December 14, 2020, that described the clinical, laboratory, and imaging features of children with COVID-19. Data were extracted independently by 2 authors. Random-effects meta-analysis models were used to report pooled results.Clinical data from 2874 children with COVID-19 from 37 articles were finally included for quantitative analyses. Fever (48.5%, 95% CI: 41.4%-55.6%) and cough (40.6%, 95% CI: 33.9%-47.5%) were the most common symptoms; asymptomatic infection and severe cases, respectively, accounted for 27.7% (95% CI: 19.7%-36.4%) patients and 1.1% of the 1933 patients included. Laboratory tests showed 5.5% (95% CI: 2.8%-8.9%) of
2020-03-08
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Department of Cardiology and Institute of Vascular Medicine, Peking University; Third Hospital, Beijing, China Department of Orthopedics, Peking University Third Hospital, Beijing, China; Research Center of Clinical Epidemiology, Peking University Third Hospital,; Beijing, China MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China;
Background: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. Methods: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data.
2020-03-08
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Department of Cardiology and Institute of Vascular Medicine, Peking University; Third Hospital, Beijing, China Department of Orthopedics, Peking University Third Hospital, Beijing, China; Research Center of Clinical Epidemiology, Peking University Third Hospital,; Beijing, China MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and; Prevention, China CDC, Beijing, China Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China;
Background: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. Methods: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data.
2020-03-03
grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Radiology, the Second Hospital of; Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Clinical Research Center, the; Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Maternal, Child and Adolescent; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Critical Medicine, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China
Previous studies have showed clinical characteristics of patients with the 2019 novel coronavirus disease (COVID-19) and the evidence of person-to-person transmission. Limited data are available for asymptomatic infections. This study aims to present the clinical characteristics of 24 cases with asymptomatic infection screened from close contacts and to show the transmission potential of asymptomatic COVID-19 virus carriers. Epidemiological investigations were conducted among all close contacts of COVID-19 patients (or suspected patients) in Nanjing, Jiangsu Province, China, from Jan 28 to Feb 9, 2020, both in clinic and in community. Asymptomatic carriers were laboratory-confirmed positive for the COVID-19 virus by testing the nucleic acid of the pharyngeal swab samples. Their clinical records, laboratory assessments, and chest CT scans were reviewed. As a result, none of the 24 asymptomatic cases presented any obvious symptoms
2020-03-03
grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Radiology, the Second Hospital of; Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Clinical Research Center, the; Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Maternal, Child and Adolescent; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Department of Critical Medicine, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.410745.30000 0004 1765 1045Nanjing Infectious Disease Center, the Second; Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China grid.89957.3a0000 0000 9255 8984Department of Epidemiology, Center for Global; Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China
Previous studies have showed clinical characteristics of patients with the 2019 novel coronavirus disease (COVID-19) and the evidence of person-to-person transmission. Limited data are available for asymptomatic infections. This study aims to present the clinical characteristics of 24 cases with asymptomatic infection screened from close contacts and to show the transmission potential of asymptomatic COVID-19 virus carriers. Epidemiological investigations were conducted among all close contacts of COVID-19 patients (or suspected patients) in Nanjing, Jiangsu Province, China, from Jan 28 to Feb 9, 2020, both in clinic and in community. Asymptomatic carriers were laboratory-confirmed positive for the COVID-19 virus by testing the nucleic acid of the pharyngeal swab samples. Their clinical records, laboratory assessments, and chest CT scans were reviewed. As a result, none of the 24 asymptomatic cases presented any obvious symptoms